Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vickery, B. H.
Right arrow Articles by Falvo, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vickery, B. H.
Right arrow Articles by Falvo, R. E.

Journal of Andrology, Vol 6, Issue 1 53-60, Copyright © 1985 by The American Society of Andrology

JOURNAL ARTICLE

Dose-response studies on male reproductive parameters in dogs with nafarelin acetate, a potent LHRH agonist

B. H. Vickery, G. I. McRae, W. V. Briones, B. B. Roberts, A. C. Worden, B. D. Schanbacher and R. E. Falvo

Adult male beagle dogs were administered daily subcutaneous injections of either 0.5 or 2.0 micrograms/kg of a potent LHRH agonist, nafarelin acetate, for 44 days. Although there was a rise in the circulating levels of the gonadotropins and of testosterone following the early injections of agonist, continued treatment caused a marked decline in acute response and basal levels of both LH and testosterone and smaller decreases in the acute FSH response. The decline in LH and testosterone was accompanied by decreases in testicular volume, ejaculated sperm count, sperm motility, ejaculate volume, and duration of ejaculation. The decline in these parameters was more rapid at 2.0 micrograms/kg than at 0.5 micrograms/kg. The profile of responses to 2.0 micrograms/kg could be superimposed on that previously shown for the injection of 10.0 micrograms/kg. At the end of treatment, prostate weights were 36% and 68% of vehicle-treated controls for high- and low-dose animals, respectively. Spermatogenesis was absent in the testes of all agonist-treated animals. Over the dose range tested, the dose-response on all parameters was characterized by a slower evolution to the same maximal effect, rather than by a partial effect. If these data can be extrapolated to man, they would suggest that administration of higher dose levels of LHRH agonists than presently reported should be explored.


This article has been cited by other articles:


Home page
 Biol. Reprod.Home page
C.A. Herbert, T.E. Trigg, M.B. Renfree, G. Shaw, D.C. Eckery, and D.W. Cooper
Effects of a Gonadotropin-Releasing Hormone Agonist Implant on Reproduction in a Male Marsupial, Macropus eugenii
Biol Reprod, June 1, 2004; 70(6): 1836 - 1842.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
T.L. Davis, M.L. Mussard, H. Jimenez-Severiano, W.J. Enright, and J.E. Kinder
Chronic Treatment with an Agonist of Gonadotropin-Releasing Hormone Enhances Luteal Function in Cattle
Biol Reprod, August 1, 2003; 69(2): 398 - 403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by The American Society of Andrology.